A Study of JNJ-73763989 in Healthy Chinese Adult Participants

Recruitment & Eligibility

Inclusion Criteria

Participant must be healthy based on physical examination, laboratory assessment, vital signs and electrocardiogram (ECG) at screening
A female participant of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [hCG]) pregnancy test at screening and a negative urine pregnancy test on Day -1
A male participant must agree not to donate sperm after enrollment (Day 1) in the study and a female participant must agree not to donate eggs (ova, oocytes) during the study until at least 90 days after receiving the study drug
Participant must not use nicotine-containing substances including tobacco products for at least 3 months prior to screening until completion of the study
Participant must have suitable veins for cannulation and/or repeated venipuncture

Exclusion Criteria

Participant with a history of cardiac arrhythmias (example, premature ventricular contractions), history of risk factors for Torsade de Pointes syndrome (example, hypokalemia, family history of long QT Syndrome)
Participant with human immunodeficiency virus infection (confirmed by antibodies) at screening
Participant with current hepatitis A infection (confirmed by hepatitis A antibody immunoglobulin M [IgM]), or hepatitis B infection (confirmed by HBsAg), or hepatitis C virus (HCV) infection (confirmed by HCV antibody), or hepatitis E infection (confirmed by hepatitis E antibody IgM) at screening
Participant has positive test result(s) for alcohol and/or drugs of abuse (including amphetamines, benzodiazepines, cocaine, cannabinoids, opioids, and methadone) at screening and Day-1
Participant has a history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant or that could prevent, limit, or confound the protocol-specified assessments. This may include but is not limited to renal dysfunction estimated Glomerular Filtration Rate (GFR) <60 millimeter per minute (mL/min) /1.73 m^2 at screening

Study & Design

Arm && Interventions

Group	Intervention	Description
Panel A: JNJ-73763989	JNJ-73763989	Participants will receive single subcutaneous (SC) injection of low dose of JNJ-73763989 on Day 1.
Panel B: J NJ-73763989	JNJ-73763989	Participants will receive single SC injection of high dose of JNJ-73763989 on Day 1.

Primary Outcome Measures

Name	Time	Method
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Up to 4 Weeks	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Urine Concentration of JNJ-73763989	Predose up to 48 hours postdose (up to Day 3)	Urine samples will be analyzed to determine concentrations of JNJ-73763989 (as the 2 triggers JNJ-73763976 and JNJ-73763924).
Plasma Concentration of JNJ-73763989	Predose up to 48 hours postdose (up to Day 3)	Plasma samples will be analyzed to determine concentrations of JNJ-73763989 (as the 2 triggers JNJ-73763976 and JNJ-73763924).

Secondary Outcome Measures

Name	Time	Method

Recruitment & Eligibility